Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
140 hedge funds and large institutions have $671M invested in Taro Pharmaceutical Industries Ltd. in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 47 increasing their positions, 53 reducing their positions, and 12 closing their positions.
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
1% more funds holding
Funds holding: 139 → 140 (+1)
6% less capital invested
Capital invested by funds: $712M → $671M (-$41.6M)
11% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 53
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
85% less call options, than puts
Call options by funds: $213K | Put options by funds: $1.38M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.6M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.75M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.26M |
| 4 |
RRAM
River Road Asset Management
Louisville,
Kentucky
|
+$1.85M |
| 5 |
AG
Aperio Group
Sausalito,
California
|
+$1.83M |
Top Sellers
TARO Hedge Fund Activity: Q2 2017 in Review
140 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q2 2017, worth a combined $671M — down 5.8% from $712M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TARO positions and 12 closed out — a net gain of 1 holder — while 47 added to existing stakes and 53 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $15.6M. The largest seller was Royal Bank of Canada, cutting an estimated $10.2M.
- 140 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q2 2017, up from 139 in Q1 2017.
- Funds reported $671M of Taro Pharmaceutical Industries Ltd. stock for Q2 2017, down 5.8% quarter-over-quarter.
- 13 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q2 2017 and 12 closed out, a net change of +1 holder.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q2 2017 was Fidelity Investments, an estimated $15.6M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q2 2017 was Royal Bank of Canada, an estimated $10.2M sold.
Based on aggregated 13F filings for Q2 2017.